Circulating inflammation markers and risk of epithelial ovarian cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 5, 2011, Pages 799-810

  Clendenen, Tess V ^a   Lundin, Eva ^b   Zeleniuch Jacquotte, Anne ^a   Koenig, Karen L ^a   Berrino, Franco ^c   Lukanova, Annekatrin ^a,d   Lokshin, Anna E ^e,f,g   Idahl, Annika ^b   Ohlson, Nina ^b   Hallmans, Goran ^b   Krogh, Vittorio ^c   Sieri, Sabina ^c   Muti, Paola ^h   Marrangoni, Adele ^e   Nolen, Brian M ^e   Liu, Mengling ^a   Shore, Roy E ^a,i   Arslan, Alan A ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UMEÅ UNIVERSITY   (Sweden)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

^h REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

ⁱ RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 2; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD DONOR; BODY MASS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RISK; CASE CONTROL STUDY; CLEAR CELL CARCINOMA; CONTROLLED STUDY; ENDOMETRIUM CANCER; FAMILY HISTORY; FEMALE; GYNECOLOGIC CANCER; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MENARCHE; MUCINOUS CARCINOMA; OVARY CANCER; PARITY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; SEROUS CANCER; UNDIFFERENTIATED CARCINOMA; VITAMIN SUPPLEMENTATION;

ADULT; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 79955751535     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-1180     Document Type: Article

References (53)

1. Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE, et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 2000;11:111-7. (Pubitemid 30112009)
2. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
3. Fernandez-Botran R. Soluble cytokine receptors: basic immunology and clinical applications. Crit Rev Clin Lab Sci 1999;36:165-224. (Pubitemid 29363806)
4. Heaney ML, Golde DW. Soluble receptors in human disease. J Leukoc Biol 1998;64:135-46. (Pubitemid 28354974)
5. McSorley MA, Alberg AJ, Allen DS, Allen NE, Brinton LA, Dorgan JF, et al. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol 2007;109:933-41. (Pubitemid 46559083)
6. Lundin E, Dossus L, Clendenen T, Krogh V, Grankvist K, Wulff M, et al. C-reactive protein and ovarian cancer: a prospective study nested in three cohorts (Sweden, USA, Italy). Cancer Causes Control 2009;20:1151-9.
7. Gu Y, Zeleniuch-Jacquotte A, Linkov F, Koenig KL, Liu M, Velikokhatnaya L, et al. Reproducibility of serum cytokines and growth factors. Cytokine 2009;45:44-9.
8. Wong HL, Pfeiffer RM, Fears TR, Vermeulen R, Ji S, Rabkin CS. Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons. Cancer Epidemiol Biomarkers Prev 2008;17:3450-6.
9. Clendenen TV, Arslan AA, Lokshin AE, Idahl A, Hallmans G, Koenig KL, et al. Temporal reliability of cytokines and growth factors in EDTA plasma. BMC Res Notes 2010;3:302-10.
10. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995;87:190-7.
11. Toniolo PG, Pasternack BS, Shore RE, Sonnenschein E, Koenig KL, Rosenberg C, et al. Endogenous hormones and breast cancer: a prospective cohort study. Breast Cancer Res Treat 1991;18Suppl 1:S23-6.
12. Hallmans G, Agren A, Johansson G, Johansson A, Stegmayr B, Jansson JH, et al. Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort-evaluation of risk factors and their interactions. Scand J Public Health Suppl 2003;61:18-24.
13. Berrino F, Muti P, Micheli A, Bolelli G, Krogh V, Sciajno R, et al. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996;88:291-6. (Pubitemid 26073374)
14. Vignali DA. Multiplexed particle-based flow cytometric assays. J Immunol Methods 2000;243:243-55.
15. Lubin JH, Colt JS, Camann D, Davis S, Cerhan JR, Severson RK, et al. Epidemiologic evaluation of measurement data in the presence of detection limits. Environ Health Perspect 2004;112:1691-6. (Pubitemid 40017291)
16. Rosner B. Percentage points for a generalized ESD many-outlier procedure. Technometrics 1983;25:165-72. (Pubitemid 13540616)
17. Rosner B, Spiegelman D, Willett WC. Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error. Am J Epidemiol 1992;136:1400-13. (Pubitemid 23046425)
18. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: John Wiley & Sons, Inc.; 1987.
19. Heaney ML, Golde DW. Soluble cytokine receptors. Blood 1996;87:847-57. (Pubitemid 26043512)
20. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006;80:227-36. (Pubitemid 44835496)
21. Peck A, Mellins ED. Plasticity of T-cell phenotype and function: the T helper type 17 example. Immunology 2010;129:147-53.
22. Espey LL. Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction. Biol Reprod 1994;50:233-8. (Pubitemid 24058476)
23. Shan W, Liu J. Inflammation: a hidden path to breaking the spell of ovarian cancer. Cell Cycle 2009;8:3107-11.
24. Hutson R, Ramsdale J, Wells M. p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathology 1995;27:367-71.
25. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001;22:255-88. (Pubitemid 32458162)
26. Murdoch WJ, Martinchick JF. Oxidative damage to DNA of ovarian surface epithelial cells affected by ovulation: carcinogenic implication and chemoprevention. Exp Biol Med (Maywood)2004;229:546-52. (Pubitemid 38736324)
27. Pothuri B, Leitao MM, Levine DA, Viale A, Olshen AB, Arroyo C, et al. Genetic analysis of the early natural history of epithelial ovarian carcinoma. PLoS One 2010;5:e10358.
28. Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. J Oncol 2010;2010:932371.
29. Salvador S, Gilks B, Kobel M, Huntsman D, Rosen B, Miller D. The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer 2009;19:58-64.
30. O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001;85:473-83. (Pubitemid 32808267)
31. Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature 2004;431:405-6. (Pubitemid 39329565)
32. Willis C, Morris JM, Danis V, Gallery ED. Cytokine production by peripheral blood monocytes during the normal human ovulatory menstrual cycle. Hum Reprod 2003;18:1173-8.
33. Omu AE, Al-Azemi MK, Makhseed M, Al-Oattan F, Ismail AA, Al- Tahir S, et al. Differential expression of T-helper cytokines in the peritoneal fluid of women with normal ovarian cycle compared with women with chronic anovulation. Acta Obstet Gynecol Scand 2003;82:603-9. (Pubitemid 36735133)
34. Abrahamsen B, Stilgren LS, Rettmer E, Bonnevie-Nielsen V, Beck- Nielsen H. Effects of the natural and artificial menstrual cycle on the production of osteoprotegerin and the bone resorptive cytokines IL- 1beta and IL-6. Calcif Tissue Int 2003;72:18-23. (Pubitemid 36918933)
35. Verthelyi D, Klinman DM. Sex hormone levels correlate with the activity of cytokine-secreting cells in vivo. Immunology 2000;100:384-90. (Pubitemid 30449954)
36. Chiu KM, Arnaud CD, Ju J, Mayes D, Bacchetti P, Weitz S, et al. Correlation of estradiol, parathyroid hormone, interleukin-6, and soluble interleukin-6 receptor during the normal menstrual cycle. Bone 2000;26:79-85.
37. Steer CV, Campbell S, Pampiglione JS, Kingsland CR, Mason BA, Collins WP. Transvaginal colour flow imaging of the uterine arteries during the ovarian and menstrual cycles. Hum Reprod 1990;5:391-5. (Pubitemid 20346821)
38. Scholtes MC, Wladimiroff JW, van Rijen HJ, Hop WC. Uterine and ovarian flow velocity waveforms in the normal menstrual cycle: a transvaginal Doppler study. Fertil Steril 1989;52:981-5. (Pubitemid 20011247)
39. Collins W, Jurkovic D, Bourne T, Kurjak A, Campbell S. Ovarian morphology, endocrine function and intra-follicular blood flow during the peri-ovulatory period. Hum Reprod 1991;6:319-24.
40. Tan SL, Zaidi J, Campbell S, Doyle P, Collins W. Blood flow changes in the ovarian and uterine arteries during the normal menstrual cycle. Am J Obstet Gynecol 1996;175(3 Pt 1):625-31.
41. Nash MA, Ferrandina G, Gordinier M, Loercher A, Freedman RS. The role of cytokines in both the normal and malignant ovary. Endocr Relat Cancer 1999;6:93-107. (Pubitemid 29197233)
42. Motro B, Itin A, Sachs L, Keshet E. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci U S A 1990;87:3092-6.
43. Barak V, Mordel N, Zajicek G, Kalichman I, Treves AJ, Laufer N. The correlation between interleukin 2 and soluble interleukin 2 receptors to oestradiol, progesterone and testosterone levels in periovulatory follicles of in vitro fertilization patients. Hum Reprod 1992;7:926-9.
44. Ripley D, Shoup B, Majewski A, Chegini N. Differential expression of interleukins IL-13 and IL-15 in normal ovarian tissue and ovarian carcinomas. Gynecol Oncol 2004;92:761-8. (Pubitemid 38251374)
45. Bornstein SR, Rutkowski H, Vrezas I. Cytokines and steroidogenesis. Mol Cell Endocrinol 2004;215:135-41. (Pubitemid 38333252)
46. Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martinez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1991;164:1038-42; discussion 42-3.
47. Gastl G, Plante M, Finstad CL, Wong GY, Federici MG, Bander NH, et al. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br J Haematol 1993;83:433-41. (Pubitemid 23080014)
48. Moradi MM, Carson LF, Weinberg B, Haney AF, Twiggs LB, Ramakrishnan S. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer 1993;72:2433-40. (Pubitemid 23299609)
49. Scambia G, Testa U, Panici PB, Martucci R, Foti E, Petrini M, et al. Interleukin-6 serum levels in patients with gynecological tumors. Int J Cancer 1994;57:318-23. (Pubitemid 24168603)
50. Tempfer C, Zeisler H, Sliutz G, Haeusler G, Hanzal E, Kainz C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol 1997;66:27-30. (Pubitemid 27329303)
51. Lambeck AJ, Crijns AP, Leffers N, Sluiter WJ, ten Hoor KA, Braid M, et al. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res 2007;13:2385-91.
52. Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:981-7. (Pubitemid 40478567)
53. Steinman L. A brief history of T(H)17, the first major revision in the T(H) 1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007;13:139-45.